

## Endnotes

### KEY DOCUMENTS

The following documents were consulted widely in the development of the operational plan:

- National HIV and Syphilis Antenatal Sero-Prevalence Survey in South Africa, 2002. Department of Health, 2003
- Full Report of the Joint Health and Treasury Task Team Charged with Examining Treatment Option to Supplement Comprehensive Care for HIV/AIDS in the Public Health Sector. Department of Health, 2003
- HIV/AIDS and STI Strategic Plan for South Africa, 2000-2005. Department of Health, 2000

### CITATIONS FOR EXECUTIVE SUMMARY

1. K. Freedberg, E. Losina, M. Weinstein. The cost-effectiveness of combination antiretroviral therapy for HIV disease. *New England Journal of Medicine* 2001; 344: 824-831
2. Actuarial Society of South Africa. ASSA2000 AIDS and Demographic Model Provincial Outputs. <http://www.assa.org.za/>. Cape Town, 2003

### CITATIONS FOR CHAPTER I

1. Zachariah R, Spielmann MP, Harries AD, Salaniponi FL. Voluntary counselling, HIV testing and sexual behaviour among patients with tuberculosis in a rural district of Malawi. *Int J Tuberc Lung Dis*. Jan 2003;7(1):65-71.
2. Nuwaha F, Kabatesi D, Muganwa M, Whalen CC. Factors influencing acceptability of voluntary counselling and testing for HIV in Bushenyi district of Uganda. *East Afr Med J*. Dec 2002;79(12):626-632.
3. Pronyk PM, Kim JC, Makhubele MB, Hargreaves JR, Mohlala R, Hausler HP. Introduction of voluntary counselling and rapid testing for HIV in rural South Africa: from theory to practice. *AIDS Care*. Dec 2002;14(6):859-865.
4. Gresenguet G, Sehonou J, Bassirou B, Longo Jde D, Malkin JE, Brogan T, Belec L. Voluntary HIV counseling and testing: experience among the sexually active population in Bangui, Central African Republic. *J Acquir Immune Defic Syndr*. Sep 1 2002;31(1):106-114.
5. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-

- month follow-up of the HIVNET 012 randomised trial. *Lancet*. Sep 13 2003;362(9387):859-868.
6. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Post-exposure Prophylaxis. *MMWR Recomm Rep*. Jun 29 2001;50(RR-11):1-52.
  7. Sherlekar S, Udipi SA. Role of nutrition in the management of HIV infection/AIDS. *J Indian Med Assoc*. Jun 2002;100(6):385-390.
  8. Lyon ME, Trexler C, Akpan-Townsend C, Pao M, Selden K, Fletcher J, Addlestone IC, D'Angelo LJ. A family group approach to increasing adherence to therapy in HIV-infected youths: results of a pilot project. *AIDS Patient Care STDS*. Jun 2003;17(6):299-308.
  9. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. *Ann Intern Med*. Dec 4 2001;135(11):954-964.
  10. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Margolick JB, Phair JP, Mellors JW. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. *J Infect Dis*. Mar 2000;181(3):872-880.
  11. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. May 24 1996;272(5265):1167-1170.
  12. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR, Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. Jun 15 1997;126(12):946-954.
  13. Egger M, Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet*. Aug 30 2003;362(9385):679-686.
  14. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. *Ann Intern Med*. Sep 3 2002;137(5 Pt 2):381-433.
  15. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. *Jama*. Jul 10 2002;288(2):222-235.
  16. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin Infect Dis*. Jul 1 2003;37(1):113-128.

17. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. Jul 13 2002;360(9327):119-129.
18. WHO Guidelines for Implementing Collaborative TB and HIV Programme Activities. 2003.
19. Harries et al. Deaths from TB in sub-Saharan African Countries With a High Prevalence of HIV-1. *Lancet* 2001, 357:1519-23.
20. Badri M, Wilson D and Wood R. Effect of HAART on the incidence of TB in South Africa: A cohort study. *Lancet* 2002 (359): 2059-2064
21. WHO. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach. 2002.
22. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. *AIDS Rev*. Apr-Jun 2002;4(2):59-63.
23. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. *J Acquir Immune Defic Syndr*. Dec 15 2002;31 Suppl 3:S112-117.
24. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. *Aids*. Jun 13 2003; 17(9):1369-1375.

## **CITATIONS FOR CHAPTER II**

1. Piwoz, Ellen G, Preble, Elizabeth A. A Review of the Literature and Recommendations for Nutritional Care and Support in Sub-Saharan Africa. 2000
2. HIV/AIDS: A Guide for Nutrition Care and Support. Food and Nutrition Education Technical Project, Academy for Education Development, Washington DC, 2001
3. *ibid.*
4. *ibid.*

## **CITATIONS FOR CHAPTER III**

1. WHO Traditional Medicine Strategy for 2000-2005.
2. Mason, F. The Complementary Project Treatment Survey, 1995.
3. Anderson et al. Patient Use and Assessment of Conventional and Alternative Therapies for HIV Infection and AIDS. *Journal of AIDS: Volume 7*:561-568, 1993.

## **CITATIONS FOR CHAPTER XIV**

1. WHO Report 2003, Global TB Control: Surveillance, planning and financing. WHO/CDS/2003.316: 109